SUNNYVALE, Calif.--(BUSINESS WIRE)--EBR Systems, Inc., developer of the world’s only wireless cardiac pacing system for heart failure, today announced that the U.S. Food and Drug Administration (FDA) ...

The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...

The simulation results presented here demonstrate the potential of the adaptive CRT device with dynamic optimization of AV and VV intervals for improving cardiac output beyond the current non-adaptive ...

AdaptivCRT® Algorithm Customizes Therapy for Heart Failure Patients and Improves Their Response Rates MINNEAPOLIS - Medtronic, Inc. today announced the U.S. Food and Drug Administration (FDA) approval ...

Known as the MADIT-CHIC study, it was the first of its kind to assess whether cardiac resynchronization therapy (CRT) could improve heart function in patients with congestive heart failure and ...

AUSTIN, Texas, Feb. 2, 2026 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an ...

Medtronic CRT-D Devices Demonstrate Survival Benefits for Mildly Symptomatic Heart Failure Patients in Two Pivotal Clinical Trials MINNEAPOLIS – Medtronic, Inc. today announced that the U.S. Food and ...

Please provide your email address to receive an email when new articles are posted on . Device-based therapy may be necessary for certain patients with NYHA class II/III heart failure with reduced ...

A pacemaker-like device restored heart function in a group of cancer survivors -- mostly women with breast cancer -- who had suffered from heart failure as a result of chemotherapy treatment, a study ...

MINNEAPOLIS -- The novel dual-function cardiac contractility modulation-defibrillator (CCM-D) for heart failure with reduced ejection fraction (HFrEF) had favorable early results in the Integra-D ...

Outcomes associated with cardiac device implantation in elderly patients have not been widely studied. A new analysis by Paul Hauptman and colleagues at St Louis University School of Medicine and ...

The U.S. Food and Drug Administration today approved the Barostim Neo System for the improvement of symptoms in patients with advanced heart failure who are not suited for treatment with other heart ...